BR112012023950A2 - formas cristalinas de um macrolídeo, e usos dos mesmos - Google Patents
formas cristalinas de um macrolídeo, e usos dos mesmosInfo
- Publication number
- BR112012023950A2 BR112012023950A2 BR112012023950A BR112012023950A BR112012023950A2 BR 112012023950 A2 BR112012023950 A2 BR 112012023950A2 BR 112012023950 A BR112012023950 A BR 112012023950A BR 112012023950 A BR112012023950 A BR 112012023950A BR 112012023950 A2 BR112012023950 A2 BR 112012023950A2
- Authority
- BR
- Brazil
- Prior art keywords
- crystalline forms
- macrolide
- macrolides
- preparing
- processes
- Prior art date
Links
- 239000003120 macrolide antibiotic agent Substances 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229940041033 macrolides Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/04—Nitro compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Cephalosporin Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
formas cristalinas de uma macrolídeos, e usos dos mesmos. a presente invenção refere-se a novas formas cristalinas de compostos de macrolídeo, e composições farmacêuticas dos mesmos. além disso, são descritos neste documento processos para preparar as formas cristalinas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31606310P | 2010-03-22 | 2010-03-22 | |
PCT/US2011/029424 WO2011119604A1 (en) | 2010-03-22 | 2011-03-22 | Crystalline forms of a macrolide, and uses therefor |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012023950A2 true BR112012023950A2 (pt) | 2016-07-05 |
Family
ID=44673574
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012023950A BR112012023950A2 (pt) | 2010-03-22 | 2011-03-22 | formas cristalinas de um macrolídeo, e usos dos mesmos |
Country Status (20)
Country | Link |
---|---|
US (4) | US8975386B2 (pt) |
EP (2) | EP3009442B1 (pt) |
JP (4) | JP5711352B2 (pt) |
KR (2) | KR102006200B1 (pt) |
CN (2) | CN108570083A (pt) |
AU (2) | AU2011232627B2 (pt) |
BR (1) | BR112012023950A2 (pt) |
CA (1) | CA2793884C (pt) |
DK (1) | DK2550286T3 (pt) |
ES (1) | ES2564097T3 (pt) |
HK (1) | HK1177937A1 (pt) |
HR (1) | HRP20160168T1 (pt) |
IL (1) | IL222018B (pt) |
MX (1) | MX361413B (pt) |
MY (1) | MY162411A (pt) |
NZ (1) | NZ602544A (pt) |
PL (1) | PL2550286T3 (pt) |
RU (1) | RU2650883C2 (pt) |
SI (1) | SI2550286T1 (pt) |
WO (1) | WO2011119604A1 (pt) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7601695B2 (en) | 2003-03-10 | 2009-10-13 | Optimer Pharmaceuticals, Inc. | Antibacterial agents |
AU2008316830B2 (en) | 2007-10-25 | 2016-03-17 | Cempra Pharmaceuticals, Inc. | Process for the preparation of macrolide antibacterial agents |
DK2358379T3 (en) | 2008-10-24 | 2016-03-07 | Cempra Pharmaceuticals Inc | BIOFORSVAR USING TRIAZOLHOLDIGE macrolides |
US9937194B1 (en) | 2009-06-12 | 2018-04-10 | Cempra Pharmaceuticals, Inc. | Compounds and methods for treating inflammatory diseases |
AU2010292010B2 (en) | 2009-09-10 | 2016-01-07 | Cempra Pharmaceuticals, Inc. | Methods for treating malaria, tuberculosis and MAC diseases |
CA2793884C (en) * | 2010-03-22 | 2019-09-10 | Cempra Pharmaceuticals, Inc. | Crystalline forms of a macrolide, and uses therefor |
DK2571506T3 (en) | 2010-05-20 | 2017-08-28 | Cempra Pharmaceuticals Inc | PROCEDURES FOR THE MANUFACTURE OF MACROLIDES AND KETOLIDES AND INTERMEDIATES |
EP2613630A4 (en) | 2010-09-10 | 2014-01-15 | Cempra Pharmaceuticals Inc | FLUOROCETOLIDES FORMING HYDROGEN LINKS TO TREAT DISEASES |
WO2013148891A1 (en) | 2012-03-27 | 2013-10-03 | Cempra Pharmaceuticals, Inc. | Parenteral formulations for administering macrolide antibiotics |
US9861616B2 (en) | 2013-03-14 | 2018-01-09 | Cempra Pharmaceuticals, Inc. | Methods for treating respiratory diseases and formulations therefor |
CN105188712A (zh) | 2013-03-15 | 2015-12-23 | 森普拉制药公司 | 用于制备大环内酯抗菌剂的收敛方法 |
CA3130061C (en) | 2013-04-04 | 2024-05-28 | President And Fellows Of Harvard College | Macrolides and methods of their preparation and use |
US20170224664A1 (en) * | 2014-08-05 | 2017-08-10 | Cempra Pharmaceuticals, Inc. | Powder oral suspension formulations of antibacterial agents |
CN104151382B (zh) * | 2014-08-08 | 2016-09-14 | 广东东阳光药业有限公司 | 一种固态大环内酯的晶型 |
CN104311611B (zh) * | 2014-08-13 | 2017-01-18 | 广东东阳光药业有限公司 | 一种制备固态大环内酯的方法 |
CA2963815A1 (en) | 2014-10-08 | 2016-04-14 | President And Fellows Of Harvard College | 14-membered ketolides and methods of their preparation and use |
CA2980315A1 (en) | 2015-03-25 | 2016-09-29 | President And Fellows Of Harvard College | Macrolides with modified desosamine sugars and uses thereof |
WO2017061431A1 (ja) * | 2015-10-05 | 2017-04-13 | 富山化学工業株式会社 | ソリスロマイシンを含む錠剤 |
EP3190122A1 (en) * | 2016-01-08 | 2017-07-12 | LEK Pharmaceuticals d.d. | A novel synthetic pathway towards solithromycin and purification thereof |
TW201811811A (zh) * | 2016-09-02 | 2018-04-01 | 森普拉製藥公司 | 製備氟酮內酯之方法 |
IL293115A (en) * | 2019-12-02 | 2022-07-01 | Aliquantumrx Inc | Salts and polymorphs of cethromycin for the treatment of disease Salts and polymorphs of cethromycin |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4331803A (en) | 1980-06-04 | 1982-05-25 | Taisho Pharmaceutical Co., Ltd. | Novel erythromycin compounds |
US4474768A (en) | 1982-07-19 | 1984-10-02 | Pfizer Inc. | N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor |
US4742049A (en) | 1986-06-04 | 1988-05-03 | Abbott Laboratories | Semisynthetic erythromycin antibiotics |
IL99995A (en) | 1990-11-21 | 1997-11-20 | Roussel Uclaf | Erythromycin derivatives, their preparation and pharmaceutical compositions containing them |
US5985844A (en) | 1992-03-26 | 1999-11-16 | Merck & Co., Inc. | Homoerythromycin A derivatives modified at the 4"-and 8A-positions |
US5527780A (en) | 1992-11-05 | 1996-06-18 | Roussel Uclaf | Erythromycin derivatives |
FR2697524B1 (fr) | 1992-11-05 | 1994-12-23 | Roussel Uclaf | Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments. |
FR2718450B1 (fr) | 1994-04-08 | 1997-01-10 | Roussel Uclaf | Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments. |
FR2719587B1 (fr) | 1994-05-03 | 1996-07-12 | Roussel Uclaf | Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments. |
US5834428A (en) | 1995-04-14 | 1998-11-10 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
FR2739620B1 (fr) | 1995-10-09 | 1997-12-19 | Roussel Uclaf | Nouveaux derives de la 5-0-desosaminyl 6-o-methyl erythronolide a, leur procede de preparation et leur application a la preparation de produits biologiquement actifs |
US6274715B1 (en) | 1995-11-08 | 2001-08-14 | Abbott Laboratories | Tricyclic erythromycin derivatives |
FR2742757B1 (fr) | 1995-12-22 | 1998-01-30 | Roussel Uclaf | Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments |
FR2745290B1 (fr) | 1996-02-28 | 1998-04-03 | Roussel Uclaf | Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments |
ATE296832T1 (de) | 1996-09-04 | 2005-06-15 | Abbott Lab | 6-o-substituierte ketoliden mit antibakteriellen wirkung |
US6407074B1 (en) | 1997-06-11 | 2002-06-18 | Pfizer Inc | C-4″-substituted macrolide derivatives |
KR20010013660A (ko) | 1997-06-11 | 2001-02-26 | 실버스타인 아써 에이. | 9-옥심 에리트로마이신 유도체 |
HN1998000086A (es) | 1997-06-11 | 1999-03-08 | Pfizer Prod Inc | Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos. |
HN1998000159A (es) | 1997-10-29 | 1999-02-09 | Monsanto Co | Derivados de 9- amino - 3 ceto eritromicina |
IL135792A0 (en) | 1997-12-01 | 2001-05-20 | Abbott Lab | 6-o-alkyl derivatives of erythronolide b |
FR2777282B1 (fr) | 1998-04-08 | 2001-04-20 | Hoechst Marion Roussel Inc | Nouveaux derives de la 2-fluoro 3-de((2,6-dideoxy 3-c-methyl 3-0-methyl-alpha-l-ribohexopyranosyl) oxyl) 6-o-methyl 3-oxo erythromycine, leur procede de preparation et leur application a la synthese de principes actifs de medicaments |
US6020521A (en) | 1998-08-26 | 2000-02-01 | Abbott Laboratories | Macrolide LHRH antagonists |
US6387885B1 (en) | 1998-08-26 | 2002-05-14 | Abbott Laboratories | 3′,3′-N-bis-desmethyl-3′-N-cycloalkyl erythromycin derivatives as LHRH antagonists |
FR2785612A1 (fr) | 1998-11-10 | 2000-05-12 | Hoechst Marion Roussel Inc | Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments |
FR2786188B1 (fr) | 1998-11-24 | 2002-10-31 | Hoechst Marion Roussel Inc | Nouveaux derives de l'erythromycine, leur procede de preparation et leur applicaion comme medicaments |
KR100317907B1 (ko) * | 1998-11-24 | 2001-12-24 | 김 완 주 | 신규한 중간체, 이를 이용한 마크로라이드계 항생제의제조방법 |
TR200102129T2 (tr) | 1998-12-10 | 2002-01-21 | Pfizer Products Inc. | Karbamat ve karbazat ketolid antibiyotikleri. |
CZ20012675A3 (cs) | 1999-01-27 | 2002-04-17 | Pfizer Products Inc. | Ketolidová antibiotika |
CA2411293A1 (en) | 1999-01-28 | 2000-07-28 | Pfizer Products Inc. | Novel azalides and methods of making same |
MXPA01010521A (es) | 1999-04-16 | 2003-08-19 | Johnson & Johnson | Antibacteriales de cetolidos. |
US6395710B1 (en) | 1999-04-16 | 2002-05-28 | Kosan Biosciences, Inc. | Macrolide antiinfective agents |
US6420535B1 (en) | 1999-06-07 | 2002-07-16 | Abbott Laboratories | 6-O-carbamate ketolide derivatives |
US6437106B1 (en) | 1999-06-24 | 2002-08-20 | Abbott Laboratories | Process for preparing 6-o-substituted erythromycin derivatives |
WO2001010878A1 (fr) | 1999-08-06 | 2001-02-15 | Taisho Pharmaceutical Co., Ltd. | Derives d'erythromycine a |
KR100336447B1 (ko) | 1999-11-24 | 2002-05-15 | 민경윤 | 클라리스로마이신의 개선된 제조방법 |
JP2001261694A (ja) | 2000-03-06 | 2001-09-26 | Pfizer Prod Inc | ケトライド抗生物質 |
EP1469008B1 (en) * | 2000-03-15 | 2006-08-30 | Hanmi Pharm. Co., Ltd. | Method of preparing a non-pharmaceutical grade clarithromycin |
US20020115621A1 (en) | 2000-08-07 | 2002-08-22 | Wei-Gu Su | Macrolide antibiotics |
GB0031312D0 (en) | 2000-12-21 | 2001-02-07 | Glaxo Group Ltd | Macrolides |
CA2447600C (en) | 2001-05-18 | 2015-10-20 | Chiron Corporation | Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics |
WO2003004509A2 (en) | 2001-07-03 | 2003-01-16 | Chiron Corporation | C12 modified erythromycin macrolides and ketolides having antibacterial activity |
US20030176327A1 (en) | 2001-10-25 | 2003-09-18 | Cassell Gail Houston | Antibiotics for treating biohazardous bacterial agents |
US20040019012A1 (en) | 2002-02-22 | 2004-01-29 | Singh Satish K. | Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride |
KR101048279B1 (ko) | 2002-05-30 | 2011-07-13 | 더 스크립스 리서치 인스티튜트 | 구리 촉매 작용하에서의 아지드와 아세틸렌과의 리게이션 |
AR043050A1 (es) | 2002-09-26 | 2005-07-13 | Rib X Pharmaceuticals Inc | Compuestos heterociclicos bifuncionales y metodos para preparar y usar los mismos |
ITMI20022292A1 (it) | 2002-10-29 | 2004-04-30 | Zambon Spa | 9a-azalidi ad attivita' antiinfiammatoria. |
US7601695B2 (en) * | 2003-03-10 | 2009-10-13 | Optimer Pharmaceuticals, Inc. | Antibacterial agents |
WO2004096823A2 (en) | 2003-04-25 | 2004-11-11 | Chiron Corporation | Novel ketolide derivatives |
WO2005007143A2 (en) | 2003-07-14 | 2005-01-27 | The Board Of Trustees Of The University Of Illinois | Use of makrolides and ketolides for the treatment of tuberculosis |
US7457520B2 (en) | 2003-07-24 | 2008-11-25 | Time Warner Cable, Inc. | Technique for providing a virtual digital video recorder service through a communications network |
US20060116336A1 (en) | 2004-03-17 | 2006-06-01 | American Pharmaceutical Partners, Inc. | Lyophilized azithromycin formulation |
SI1742957T1 (sl) | 2004-04-28 | 2008-04-30 | Alembic Ltd | Postopek za pripravo telitromicina |
EP1794171A2 (en) | 2004-07-28 | 2007-06-13 | Ranbaxy Laboratories, Ltd. | Ketolide derivatives as antibacterial agents |
AP2007004026A0 (en) * | 2004-12-21 | 2007-06-30 | Pfizer Prod Inc | Macrolides |
DE602006016231D1 (de) | 2005-01-14 | 2010-09-30 | Glaxosmithkline Zagreb | 9a-carbamoyl-y-aminopropyl- und 9a-thiocarbamoyl-y-aminopropyl-azalide mit antimalaria-aktivität |
WO2007039914A2 (en) | 2005-10-06 | 2007-04-12 | Alembic Limited | Novel polymorphs of telithromycin |
WO2007059307A2 (en) * | 2005-11-15 | 2007-05-24 | Teva Pharmaceutical Industries Ltd. | Crystalline and amorphous forms of telithromycin |
EP1954294A2 (en) | 2005-11-23 | 2008-08-13 | Ranbaxy Laboratories Limited | Use of macrolide derivatives for treating acne |
DOP2006000268A (es) | 2005-12-22 | 2007-07-31 | Pfizer Prod Inc | Agentes antibacterianos |
CN101129383B (zh) | 2006-08-25 | 2014-04-02 | 天津和美生物技术有限公司 | 含氨基糖苷类抗生素的抗生素复方 |
US7742562B2 (en) * | 2007-06-27 | 2010-06-22 | Accuray Incorporated | Lower-torso assembly of a treatment couch useable in an X-ray environment |
EP2220104A1 (en) * | 2007-10-25 | 2010-08-25 | Sandoz AG | Process for the production of telithromycin |
AU2008316830B2 (en) | 2007-10-25 | 2016-03-17 | Cempra Pharmaceuticals, Inc. | Process for the preparation of macrolide antibacterial agents |
DK2358379T3 (en) * | 2008-10-24 | 2016-03-07 | Cempra Pharmaceuticals Inc | BIOFORSVAR USING TRIAZOLHOLDIGE macrolides |
AU2011224238B2 (en) | 2010-03-10 | 2015-11-26 | Cempra Pharmaceuticals, Inc. | Parenteral formulations of macrolide antibiotics |
CA2793884C (en) * | 2010-03-22 | 2019-09-10 | Cempra Pharmaceuticals, Inc. | Crystalline forms of a macrolide, and uses therefor |
-
2011
- 2011-03-22 CA CA2793884A patent/CA2793884C/en not_active Expired - Fee Related
- 2011-03-22 PL PL11760068T patent/PL2550286T3/pl unknown
- 2011-03-22 KR KR1020127027222A patent/KR102006200B1/ko active IP Right Grant
- 2011-03-22 EP EP15194057.4A patent/EP3009442B1/en active Active
- 2011-03-22 EP EP11760068.4A patent/EP2550286B1/en not_active Revoked
- 2011-03-22 RU RU2012144614A patent/RU2650883C2/ru not_active IP Right Cessation
- 2011-03-22 MY MYPI2012004183A patent/MY162411A/en unknown
- 2011-03-22 WO PCT/US2011/029424 patent/WO2011119604A1/en active Application Filing
- 2011-03-22 ES ES11760068.4T patent/ES2564097T3/es active Active
- 2011-03-22 BR BR112012023950A patent/BR112012023950A2/pt not_active Application Discontinuation
- 2011-03-22 JP JP2013501396A patent/JP5711352B2/ja active Active
- 2011-03-22 CN CN201810569806.0A patent/CN108570083A/zh active Pending
- 2011-03-22 US US13/636,510 patent/US8975386B2/en not_active Expired - Fee Related
- 2011-03-22 KR KR1020187025895A patent/KR20180101643A/ko not_active Application Discontinuation
- 2011-03-22 MX MX2012010895A patent/MX361413B/es active IP Right Grant
- 2011-03-22 SI SI201130745T patent/SI2550286T1/sl unknown
- 2011-03-22 NZ NZ602544A patent/NZ602544A/en not_active IP Right Cessation
- 2011-03-22 DK DK11760068.4T patent/DK2550286T3/en active
- 2011-03-22 AU AU2011232627A patent/AU2011232627B2/en not_active Ceased
- 2011-03-22 CN CN2011800174629A patent/CN103080122A/zh active Pending
-
2012
- 2012-09-20 IL IL222018A patent/IL222018B/en not_active IP Right Cessation
-
2013
- 2013-05-13 HK HK13105658.7A patent/HK1177937A1/xx not_active IP Right Cessation
- 2013-05-22 US US13/900,147 patent/US8759500B2/en not_active Expired - Fee Related
-
2014
- 2014-11-14 JP JP2014231987A patent/JP6121387B2/ja active Active
-
2015
- 2015-09-21 US US14/859,736 patent/US20160244472A1/en not_active Abandoned
-
2016
- 2016-02-16 HR HRP20160168T patent/HRP20160168T1/hr unknown
- 2016-06-15 AU AU2016203986A patent/AU2016203986B2/en not_active Ceased
- 2016-12-16 JP JP2016244733A patent/JP2017081953A/ja active Pending
-
2018
- 2018-02-26 US US15/904,826 patent/US20190040096A1/en not_active Abandoned
-
2019
- 2019-09-09 JP JP2019163614A patent/JP2020002168A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012023950A2 (pt) | formas cristalinas de um macrolídeo, e usos dos mesmos | |
BR112018003343A2 (pt) | compostos heteroarila como inibidores de irak e usos dos mesmos | |
BR112018003812A2 (pt) | compostos de heteroarila como inibidores de irak e usos dos mesmos | |
BR112017006305A2 (pt) | compostos heteroarila como inibidores de btk e usos dos mesmos | |
BR112014021531A8 (pt) | composto, composição farmacêutica e usos dos mesmos | |
BR102015032361A8 (pt) | Compostos de quinazolina, usos dos mesmos, composição farmacêutica, kit e artigo de manufatura | |
BR112015001101A2 (pt) | formas cristalinas de um inibidor de prolil hidroxilase | |
BR112019024747A2 (pt) | formulações de dose fixa | |
UA113651C2 (xx) | Макроциклічні пурини для лікування вірусних інфекцій | |
BR112014003331A2 (pt) | compostos, processos de preparação de compostos de fórmula i, composições agroquímicas e usos de compostos de fórmulas i ou viii | |
BRPI0910388A2 (pt) | agentes terapêutico antivirais. | |
EA201491486A1 (ru) | Производные пиперидинопиримидина для лечения вирусных инфекций | |
BR112014010290B8 (pt) | Composição farmacêutica na forma de dispersão sólida de ativos específicos em polímeros específicos e uso da composição farmacêutica | |
BR112014007134A2 (pt) | usos de um composto da fórmula (b), compostos, composição farmacêutica, método de preparação do composto e uso de uma quantidade efetiva de um composto | |
BR112015005168A2 (pt) | Derivados de c17-alcanodiila e alquenodiila de ácido oleanólico e métodos de uso dos mesmos | |
BR112014006321A2 (pt) | composições de wnt e usos terapêuticos de tal composição | |
IN2014CN04530A (pt) | ||
BR112014013085A2 (pt) | forma cristalina do ticagrelor, processo para a preparação da forma cristalina do ticagrelor, composição farmacêutica e processo para preparar uma composição farmacêutica | |
WO2013134534A3 (en) | Solid state forms of cabazitaxel and processes for preparation thereof | |
MX2013002948A (es) | Composiciones farmaceuticas y nutraceuticas de acido abscisico. | |
BR112012028524A2 (pt) | composições farmacêuticas, respectivos usos e métodos de preparação, composição sólida solúvel em água e kits | |
MX2014010433A (es) | Nueva forma cristalina de sulfato de sitagliptina. | |
BR112016001876A2 (pt) | composto de benzoxaborol tricíclico, método de preparação e uso do mesmo | |
EA201600394A1 (ru) | Трициклические соединения пиперидина | |
WO2013128379A3 (en) | Crystalline polymorphic forms of linagliptin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25G | Requested change of headquarter approved |
Owner name: CEMPRA PHARMACEUTICALS, INC. (US) |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 10A ANUIDADE. |
|
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |